Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSI) EBIT Margin (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of EBIT Margin data on record, last reported at 24.77% in Q4 2025.

  • For Q4 2025, EBIT Margin rose 6699.0% year-over-year to 24.77%; the TTM value through Dec 2025 reached 59.68%, up 6320.0%, while the annual FY2025 figure was 59.68%, 6320.0% up from the prior year.
  • EBIT Margin reached 24.77% in Q4 2025 per TLSI's latest filing, up from 77.94% in the prior quarter.
  • Across five years, EBIT Margin topped out at 24.77% in Q4 2025 and bottomed at 364.91% in Q4 2022.
  • Average EBIT Margin over 4 years is 177.78%, with a median of 118.91% recorded in 2024.
  • Peak YoY movement for EBIT Margin: surged 24065bps in 2024, then surged 4098bps in 2025.
  • A 4-year view of EBIT Margin shows it stood at 364.91% in 2022, then skyrocketed by 32bps to 249.05% in 2023, then skyrocketed by 63bps to 91.76% in 2024, then surged by 73bps to 24.77% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 24.77% in Q4 2025, 77.94% in Q3 2025, and 65.39% in Q2 2025.